Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "TYSABRI (Natalizumab), Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
"TYSABRI (Natalizumab), Drug Insight and Market Forecast - 2032" report provides comprehensive insights about TYSABRI (Natalizumab) for Crohn's disease (CD) in the 7MM.
A detailed picture of the TYSABRI (Natalizumab) for Crohn's disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the TYSABRI (Natalizumab) for Crohn's disease (CD).
The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TYSABRI (Natalizumab) market forecast, analysis for Crohn's disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn's disease (CD).
Drug Summary
Natalizumab is a recombinant humanized IgG4 monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. The molecular weight of natalizumab is 149 kilodaltons.
In Crohn's disease, the interaction of the a4b7 integrin with the endothelial receptor MAdCAM1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of the disease. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to the gut lymph tissue found in Peyer's patches.
MAdCAM-1 expression has been found to be increased at active sites of inflammation in patients with CD, which suggests it may play a role in the recruitment of leukocytes to the mucosa and contribute to the inflammatory response characteristic of CD. The clinical effect of natalizumab in CD may therefore be secondary to blockade of the molecular interaction of the a4b7-integrin receptor with MAdCAM-1 expressed on the venular endothelium at inflammatory foci. VCAM-1 expression has been found to be upregulated on colonic endothelial cells in a mouse model of IBD and appears to play a role in leukocyte recruitment to sites of inflammation. The role of VCAM-1 in CD, however, is not clear.
Scope of the Report
- A comprehensive product overview including the TYSABRI (Natalizumab) description, mechanism of action, dosage and administration, research and development activities in Crohn's disease (CD).
- Elaborated details on TYSABRI (Natalizumab) regulatory milestones and other development activities have been provided in this report.
- The report also highlights the TYSABRI (Natalizumab) research and development activity in Crohn's disease (CD) in detail across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around TYSABRI (Natalizumab).
- The report contains forecasted sales of TYSABRI (Natalizumab) for Crohn's disease (CD) till 2032.
- Comprehensive coverage of the late-stage emerging therapies for Crohn's disease (CD).
- The report also features the SWOT analysis with analyst views for TYSABRI (Natalizumab) in Crohn's disease (CD).
TYSABRI (Natalizumab) Analytical Perspective
In-depth TYSABRI (Natalizumab) Market Assessment
This report provides a detailed market assessment of TYSABRI (Natalizumab) in Crohn's disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.
TYSABRI (Natalizumab) Clinical Assessment
The report provides the clinical trials information of TYSABRI (Natalizumab) in Crohn's disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for Crohn's disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TYSABRI (Natalizumab) dominance.
- Other emerging products for Crohn's disease (CD) are expected to give tough market competition to TYSABRI (Natalizumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TYSABRI (Natalizumab) in Crohn's disease (CD).
- Our in-depth analysis of the forecasted sales data of TYSABRI (Natalizumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TYSABRI (Natalizumab) in Crohn's disease (CD).
Key Questions Answered
- What is the product type, route of administration and mechanism of action of TYSABRI (Natalizumab)?
- What is the clinical trial status of the study related to TYSABRI (Natalizumab) in Crohn's disease (CD) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TYSABRI (Natalizumab) development?
- What are the key designations that have been granted to TYSABRI (Natalizumab) for Crohn's disease (CD)?
- What is the forecasted market scenario of TYSABRI (Natalizumab) for Crohn's disease (CD)?
- What are the forecasted sales of TYSABRI (Natalizumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available in Crohn's disease (CD) and how are they giving competition to TYSABRI (Natalizumab) for Crohn's disease (CD)?
- Which are the late-stage emerging therapies under development for the treatment of Crohn's disease (CD)?
Key Topics Covered:
1. Report Introduction
2. TYSABRI (Natalizumab) Overview
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical Studies
2.2.2. Clinical Trials Information
2.2.3. Safety and Efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. TYSABRI (Natalizumab) Market Assessment
5.1. Market Outlook of TYSABRI (Natalizumab) in Crohn's Disease (CD)
5.2. 7MM Market Analysis
5.2.1. Market Size of TYSABRI (Natalizumab) in the 7MM for Crohn's Disease (CD)
5.3. Country-wise Market Analysis
5.3.1. Market Size of TYSABRI (Natalizumab) in the United States for Crohn's Disease (CD)
5.3.2. Market Size of TYSABRI (Natalizumab) in Germany for Crohn's Disease (CD)
5.3.3. Market Size of TYSABRI (Natalizumab) in France for Crohn's Disease (CD)
5.3.4. Market Size of TYSABRI (Natalizumab) in Italy for Crohn's Disease (CD)
5.3.5. Market Size of TYSABRI (Natalizumab) in Spain for Crohn's Disease (CD)
5.3.6. Market Size of TYSABRI (Natalizumab) in the United Kingdom for Crohn's Disease (CD)
5.3.7. Market Size of TYSABRI (Natalizumab) in Japan for Crohn's Disease (CD)
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/481smn
